Skip to Content
Merck
  • Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.

Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research (2015-01-31)
Brianne R O'Leary, Melissa A Fath, Andrew M Bellizzi, Jennifer E Hrabe, Anna M Button, Bryan G Allen, Adam J Case, Sean Altekruse, Brett A Wagner, Garry R Buettner, Charles F Lynch, Brenda Y Hernandez, Wendy Cozen, Robert A Beardsley, Jeffery Keene, Michael D Henry, Frederick E Domann, Douglas R Spitz, James J Mezhir
ABSTRACT

Pancreatic ductal adenocarcinoma (PDA) cells are known to produce excessive amounts of reactive oxygen species (ROS), particularly superoxide, which may contribute to the aggressive and refractory nature of this disease. Extracellular superoxide dismutase (EcSOD) is an antioxidant enzyme that catalyzes the dismutation of superoxide in the extracellular environment. This study tests the hypothesis that EcSOD modulates PDA growth and invasion by modifying the redox balance in PDA. We evaluated the prognostic significance of EcSOD in a human tissue microarray (TMA) of patients with PDA. EcSOD overexpression was performed in PDA cell lines and animal models of disease. The impact of EcSOD on PDA cell lines was evaluated with Matrigel invasion in combination with a superoxide-specific SOD mimic and a nitric oxide synthase (NOS) inhibitor to determine the mechanism of action of EcSOD in PDA. Loss of EcSOD expression is a common event in PDA, which correlated with worse disease biology. Overexpression of EcSOD in PDA cell lines resulted in decreased invasiveness that appeared to be related to reactions of superoxide with nitric oxide. Pancreatic cancer xenografts overexpressing EcSOD also demonstrated slower growth and peritoneal metastasis. Overexpression of EcSOD or treatment with a superoxide-specific SOD mimic caused significant decreases in PDA cell invasive capacity. These results support the hypothesis that loss of EcSOD leads to increased reactions of superoxide with nitric oxide, which contributes to the invasive phenotype. These results allow for the speculation that superoxide dismutase mimetics might inhibit PDA progression in human clinical disease.

MATERIALS
Product Number
Brand
Product Description

Supelco
L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
L-Arginine
Sigma-Aldrich
Tantalum(V) ethoxide, 99.98% trace metals basis
Sigma-Aldrich
L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Arginine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Arginine, 99%, FCC, FG
Sigma-Aldrich
Nω-Nitro-L-arginine, ≥98% (TLC)
Sigma-Aldrich
L-Arginine, reagent grade, ≥98%
Supelco
N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material
Tantalum(V) ethoxide, packaged for use in deposition systems
Sigma-Aldrich
N-Acetyl-L-cysteine, Sigma Grade, ≥99% (TLC), powder
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
N-Acetyl-L-cysteine, BioXtra, ≥99% (TLC)
USP
Acetylcysteine, United States Pharmacopeia (USP) Reference Standard
Acetylcysteine, European Pharmacopoeia (EP) Reference Standard
Isoflurane, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Amyloid Protein Non-Aβ Component, ≥80% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Sigma-Aldrich
3-Nitro-L-tyrosine, crystalline
Sigma-Aldrich
3-(Benzyldimethylammonio)propanesulfonate, BioXtra, ≥99.0% (HPCE)
Sigma-Aldrich
Anti-Nitrotyrosine Antibody, Upstate®, from rabbit